tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Jun 4;ciaa726.
doi: 10.1093/cid/ciaa726. Online ahead of print.
On Setting Expectations for a SARS-CoV-2 Vaccine
David H Canaday[SUP] 1 2 [/SUP], Stefan Gravenstein[SUP] 3 [/SUP]
Affiliations
Abstract
The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov. The long-term strategy to handle COVID-19 will almost certainly rely on vaccines. But, what type of protection can we realistically expect to achieve from vaccines and when?
Keywords: COVID-19; SARS-CoV-2; T cells; vaccine.
. 2020 Jun 4;ciaa726.
doi: 10.1093/cid/ciaa726. Online ahead of print.
On Setting Expectations for a SARS-CoV-2 Vaccine
David H Canaday[SUP] 1 2 [/SUP], Stefan Gravenstein[SUP] 3 [/SUP]
Affiliations
- PMID: 32497168
- DOI: 10.1093/cid/ciaa726
Abstract
The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In under 6 months, since SARS-CoV-2 was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development with 9 already recruiting into clinical trials posted on clinicaltrials.gov. The long-term strategy to handle COVID-19 will almost certainly rely on vaccines. But, what type of protection can we realistically expect to achieve from vaccines and when?
Keywords: COVID-19; SARS-CoV-2; T cells; vaccine.